Tenax Therapeutics (NASDAQ:TENX) Raised to “Strong-Buy” at Lifesci Capital

Tenax Therapeutics (NASDAQ:TENX) was upgraded by Lifesci Capital to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

TENX has been the subject of a number of other reports. Guggenheim reaffirmed a “buy” rating and set a $25.00 price target (up from $14.00) on shares of Tenax Therapeutics in a research report on Wednesday, December 17th. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a research note on Tuesday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $22.50.

Tenax Therapeutics Stock Performance

Shares of TENX stock opened at $14.19 on Thursday. The company has a market capitalization of $88.55 million, a price-to-earnings ratio of -10.67 and a beta of 1.41. Tenax Therapeutics has a 52-week low of $4.63 and a 52-week high of $18.38. The company has a 50-day simple moving average of $13.30 and a two-hundred day simple moving average of $9.90.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($1.26) by $0.88. On average, sell-side analysts forecast that Tenax Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Investors Weigh In On Tenax Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Perceptive Advisors LLC bought a new position in Tenax Therapeutics during the fourth quarter valued at $5,353,000. Siren L.L.C. raised its stake in shares of Tenax Therapeutics by 21.2% in the fourth quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company’s stock valued at $5,207,000 after buying an additional 74,700 shares during the period. Boothbay Fund Management LLC bought a new stake in shares of Tenax Therapeutics in the third quarter valued at $2,680,000. Millennium Management LLC lifted its position in shares of Tenax Therapeutics by 34.2% during the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock valued at $2,387,000 after buying an additional 79,998 shares during the last quarter. Finally, Marshall Wace LLP lifted its position in shares of Tenax Therapeutics by 68.2% during the 4th quarter. Marshall Wace LLP now owns 298,153 shares of the specialty pharmaceutical company’s stock valued at $3,634,000 after buying an additional 120,944 shares during the last quarter. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.